Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
David Simmons, President at Pfizer's Established Products Business Unit says he is very positive about his company's deals struck earlier this year with Aurobindo and Claris. The two Indian companies will help Pfizer bulk up more than 100 oral and injectable formulations and turn the business unit cash positive in the next two to three years. Pfizer will sell the loss-of-exclusivity products through its Greenstone arm in the United States will likely launch those in Europe, Japan and a host of emerging markets. PharmAsia News' India bureau sat down with Simmons to find out more about Pfizer's pipeline and plans in India.
You may also be interested in...
Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.
MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab
Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.
MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab
After Teaming Up With Aurobindo And Claris, Pfizer Now Talks To Cipla On Supply Deal
MUMBAI - After signing long-term manufacturing and supply arrangements with India's Claris and Aurobindo Pharma, the world's largest drug maker, Pfizer, may select Cipla as a third partner to grow the number of products being sold through its Established Products Business Unit